DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2024” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Pancreatic Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pancreatic Cancer Pipeline Outlook
Key Takeaways from the Pancreatic Cancer Pipeline Report
Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs
Pancreatic Cancer Emerging Drugs Profile
Pamrevlumab: FibroGen
Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.
Devimistat: Cornerstone Pharmaceuticals
CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria – the energy machinery of the cells – to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.
Masitinib: AB Science
Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.
SBP-101: Panbela Therapeutics
Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.
TAS-102: Taiho Pharmaceutical Co., Ltd.
TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.
RAIN-32: Rain Oncology
RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.
IMX-110: Immix Biopharma
IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).
Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Pancreatic Cancer Products have been categorized under various Molecule types such as
Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers
Scope of the Pancreatic Cancer Pipeline Report
Get the latest on Pancreatic Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pancreatic Cancer Companies, Key Products and Unmet Needs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/
